Aventis Behring Gmbh

Zlb Behring Gmbh

J&uuml;rgen R&ouml;misch

Annette Feussner

Gerhard Dickneite

Harald Stauss

Wiegand Lang

Stephen Poole

Peter Gronski

Bernhard Vohwinkel

Pauline Sxouter

Elaine Gray

Hans-Arnold St&ouml;hr

Joachim R&ouml;der

Albrecht Gr&ouml;ner

Hubert Nettelhoff

Barbara Kalina

Michel Grandgeorge

Wilfried Freudenberg

Juliana Djordjevich

Jean Luc Veron

J&ouml;rg Weisse

Werner Thill

Eric-Paul P&acirc;ques

Robert Bartlett

Gregory S Rood

Manfred Konrad

Peter Kappus

A monoclonal antibody has been developed which only specifically binds activated factor VII, and not factor VII, and which does not bind to an activated factor VII which is complexed with antithrombin III. This monoclonal antibody is isolated from the hybridoma cell line DSM ACC 2332. It can be used for qualitatively and quantitatively detecting factor VIIa in body fluids, blood coagulation preparations or the intermediate stages in the production of these preparations, on cell surfaces or in tissues, and can also be used as a humanized monoclonal antibody in therapeutic preparations.

Monoclonal antibody which is specific for activated coagulation factor VII, and its use

A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.

Pharmaceutical preparation for the treatment of inflammatory processes

The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.

Process for purifying factor VII and activated factor VII

A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin.

Protease for activating clotting factor VII

A stabilized antithrombin III preparation is described which is protected against a loss of action during pasteurization by the addition of stabilizers which consist of one or more saccharides in a mixture with more than 0.5 mol/l of one or more amino acids from the group consisting of arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts, it also being possible to additionally add glycine or glutamine to each of these amino acids.

Stabilized antithrombin III preparation

A process for the preparation of a protein solution is described which is not prone to flock or particle formation even on heat treatment, the heat treatment being carried out in a glass vessel which has been rinsed out beforehand with a detergent solution and then with distilled water or another detergent-free solvent.

Process for the preparation of a protein solution

Process for dissolving albumin flakes in a liquid and arrangement for carrying out the process

The invention relates to the use of complement inhibitors, especially of C1 inactivator or of factors I or H, for the preparation of a pharmaceutical and for the prophylaxis and therapy of chronic inflammatory intestinal disorders, inflammatory skin disorders and purpura.

Use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura

A process for separating HIV from a fluid is described, in which the HIV is bound to a C1 esterase inhibitor immobilized on a support material. The process can be carried out both for the preparation of HIV-free blood donations and therapeutically for the reduction of the virus load in the blood by means of a blood lavage under the conditions of an extracorporeal blood circulation. The C1 esterase inhibitor can be bonded to a support material which is customary in affinity chromatography or to the fibers of a filter.

Process for separating HIV from a fluid

Growing community of inventors

Marburg, Germany

Jürgen Römisch

Growing community of inventors

Marburg, Germany

J&uuml;rgen R&ouml;misch

Jürgen Römisch